Effect of APOE genotype on lipid levels in patients with coronary heart disease during a 3-week inpatient rehabilitation program

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 2, 2008, Pages 222-227

  Vossen, C Y ^a   Hoffmann, M M ^b   Hahmann, H ^c   Wusten B ^d   Rothenbacher, D ^a   Brenner, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c Klinik Schwabenland   (Germany)

^d Klinik Am Südpark   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; APOE GENE; ARTICLE; CHOLESTEROL BLOOD LEVEL; DECISION MAKING; DIAGNOSTIC VALUE; FEMALE; GENE; GENOTYPE; HEART REHABILITATION; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STANDARDIZATION;

ADULT; AGED; ALLELES; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DECISION MAKING; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENOTYPE; GERMANY; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; INPATIENTS; LINEAR MODELS; LOVASTATIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; PYRIDINES; PYRROLES; SIMVASTATIN; TRIGLYCERIDES;

EID: 49149102385     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.31     Document Type: Article

References (31)

1. Schaefer, E.J. Lipoproteins, nutrition, and heart disease. Am. J. Clin. Nutr. 75, 191-212 (2002).
2. Ades, P.A. Cardiac rehabilitation and secondary prevention of coronary heart disease. N. Engl. J. Med. 345, 892-902 (2001).
3. Masson, L.F., McNeill, G. & Avenell, A. Genetic variation and the lipid response to dietary intervention: a systematic review. Am. J. Clin. Nutr. 77, 1098-1111 (2003).
4. Ordovas, J.M. & Mooser, V. The APOE locus and the pharmacogenetics of lipid response. Curr. Opin. Lipidol. 13, 113-117 (2002).
5. Smith, J.D. Apolipoprotein E4: an allele associated with many diseases. Ann. Med. 32, 118-127 (2000).
6. Lopez-Miranda, J. et al. Effect of apolipoprotein E phenotype on diet-induced lowering of plasma low density lipoprotein cholesterol. J. Lipid. Res. 35, 1965-1975 (1994).
7. Ordovas, J.M. & Schaefer, E.J. Treatment of dyslipidemia: genetic interactions with diet and drug therapy. Curr. Atheroscler. Rep. 1, 16-23 (1999).
8. Nicklas, B.J., Ferrell, R.E., Bunyard, L.B., Berman, D.M., Dennis, K.E. & Goldberg, A.P. Effects of apolipoprotein E genotype on dietary-induced changes in high-density lipoprotein cholesterol in obese postmenopausal women. Metabolism 51, 853-858 (2002).
9. Ordovas, J.M. The quest for cardiovascular health in the genomic era: nutrigenetics and plasma lipoproteins. Proc. Nutr. Soc. 63, 145-152 (2004).
10. Humphries, S.E., Cooper, J.A., Talmud, P.J. & Miller, G.J. Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin. Chem. 53, 8-16 (2007).
11. Davignon, J. Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler. Thromb. Vasc. Biol. 25, 267-269 (2005).
12. Mahley, R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630 (1988).
13. Schneider, W.J. et al. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J. Clin. Invest. 68, 1075-1085 (1981).
14. Lahoz, C. et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154, 529-537 (2001).
15. Gerdes, L.U. et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 101, 1366-1371 (2000).
16. Song, Y., Stampfer, M.J. & Liu, S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 141, 137-147 (2004).
17. Masson, L.F. & McNeill, G. The effect of genetic variation on the lipid response to dietary change: recent findings. Curr. Opin. Lipidol. 16, 61-67 (2005).
18. Saito, M. et al. Effect of apolipoprotein E4 allele on plasma LDL cholesterol response to diet therapy in type 2 diabetic patients. Diabetes Care 27, 1276-1280 (2004).
19. Carmena, R., Roederer, G., Mailloux, H., Lussier-Cacan, S. & Davignon, J. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 42, 895-901 (1993).
20. Ordovas, J.M. et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 113, 157-166 (1995).
21. Ballantyne, C.M. et al. Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J. Am. Coll. Cardiol. 36, 1572-1578 (2000).
22. De Knijff, P. et al. Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 83, 89-97 (1990).
23. Peña, R. et al. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting. J. Intern. Med. 251, 518-525 (2002).
24. Sanllehy, C. et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia. Metabolism 47, 560-565 (1998).
25. Humphries, S.E., Talmud, P.J., Hawe, E., Bolla, M., Day, I.N. & Miller, G.J. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 358, 115-119 (2001).
26. Corella, D. et al. Environmental factors modulate the effect of the APOE genetic polymorphism on plasma lipid concentrations: ecogenetic studies in a Mediterranean Spanish population. Metabolism 50, 936-944 (2001).
27. Srinivasan, S.R., Ehnholm, C., Elkasabany, A. & Berenson, G.S. Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: The Bogalusa Heart Study. Metabolism 50, 696-702 (2001).
28. Streja, L., Packard, C.J., Shepherd, J., Cobbe, S., Ford, I. & WOSCOPS Group. Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS). Am. J. Cardiol. 90, 731-736 (2002).
29. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
30. Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).
31. Zivelin, A., Rosenberg, N., Peretz, H., Amit, Y., Kornbrot, N. & Seligsohn, U. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. Clin. Chem. 43, 1657-1659 (1997).